awmsg logo



melatonin (Slenyto®)


Reference No. 3947

Publication date:
29/11/2019


Appraisal information

melatonin (Slenyto®) 1 mg prolonged-release tablet
melatonin (Slenyto®) 5 mg prolonged-release tablet


Company: Flynn Pharma Ltd
BNF category: Central nervous system
NMG meeting date: 09/10/2019
AWMSG meeting date: 13/11/2019
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 1519
Ratification by Welsh Government: 28/11/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Melatonin (Slenyto®) is not recommended for use within NHS Wales for the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and/or Smith Magenis syndrome, where sleep hygiene measures have been insufficient. The case for cost-effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download